Minckwitz, G. v., Loibl, S., Untch, M., Eidtmann, H., Rezai, M., Fasching, P. A., . . . Gerber, B. (2016). Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto). Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).
Chicago-Zitierstil (17. Ausg.)Minckwitz, G. von, et al. Survival After Neoadjuvant Chemotherapy with or Without Bevacizumab or Everolimus for HER2-negative Primary Breast Cancer (GBG 44–GeparQuinto). Erlangen: Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2016.
MLA-Zitierstil (9. Ausg.)Minckwitz, G. von, et al. Survival After Neoadjuvant Chemotherapy with or Without Bevacizumab or Everolimus for HER2-negative Primary Breast Cancer (GBG 44–GeparQuinto). Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2016.